9,709 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Bought by Intech Investment Management LLC

Intech Investment Management LLC purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 9,709 shares of the company’s stock, valued at approximately $388,000.

Several other large investors have also added to or reduced their stakes in the stock. Pacer Advisors Inc. boosted its holdings in shares of Harmony Biosciences by 0.6% during the 2nd quarter. Pacer Advisors Inc. now owns 2,509,609 shares of the company’s stock valued at $75,715,000 after buying an additional 14,695 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Harmony Biosciences by 13.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after buying an additional 112,197 shares during the last quarter. American Century Companies Inc. raised its position in Harmony Biosciences by 53.7% in the 2nd quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock worth $20,562,000 after buying an additional 238,140 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Harmony Biosciences by 56.7% during the 2nd quarter. Renaissance Technologies LLC now owns 595,800 shares of the company’s stock valued at $17,975,000 after purchasing an additional 215,700 shares during the last quarter. Finally, LSV Asset Management increased its position in shares of Harmony Biosciences by 72.5% during the 2nd quarter. LSV Asset Management now owns 578,246 shares of the company’s stock valued at $17,446,000 after purchasing an additional 243,100 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

Harmony Biosciences Stock Down 1.8 %

HRMY stock opened at $34.50 on Wednesday. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The stock has a market capitalization of $1.97 billion, a PE ratio of 16.35, a price-to-earnings-growth ratio of 0.65 and a beta of 0.79. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The company has a fifty day moving average of $35.03 and a 200-day moving average of $33.83.

Harmony Biosciences (NASDAQ:HRMY) last released its earnings results on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $186.00 million during the quarter, compared to analysts’ expectations of $184.07 million. During the same quarter last year, the business earned $0.63 EPS. The business’s revenue was up 16.0% on a year-over-year basis. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.36 EPS for the current year.

Insider Activity at Harmony Biosciences

In related news, insider Jeffrey Dierks sold 21,496 shares of the firm’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $40.47, for a total value of $869,943.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 30.80% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Oppenheimer reissued an “outperform” rating and issued a $59.00 target price (up from $56.00) on shares of Harmony Biosciences in a report on Wednesday, October 30th. UBS Group began coverage on shares of Harmony Biosciences in a research note on Tuesday, September 10th. They issued a “buy” rating and a $56.00 price objective for the company. Cantor Fitzgerald lifted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Mizuho lifted their price target on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, October 10th. Finally, Raymond James reiterated an “outperform” rating and set a $40.00 price objective on shares of Harmony Biosciences in a research note on Thursday, October 10th. Two equities research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.